Erste Asset Management GmbH purchased a new position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,900 shares of the company’s stock, valued at approximately $133,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Quest Partners LLC increased its holdings in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the period. Algert Global LLC increased its holdings in Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after buying an additional 4,340 shares during the period. Creative Planning increased its holdings in Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock worth $231,000 after buying an additional 4,699 shares during the period. Nisa Investment Advisors LLC increased its holdings in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the period. Finally, Los Angeles Capital Management LLC increased its holdings in Replimune Group by 8.1% in the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after buying an additional 5,410 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.
Insider Buying and Selling at Replimune Group
In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 8.80% of the stock is currently owned by insiders.
Replimune Group Trading Up 0.2 %
Replimune Group (NASDAQ:REPL – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Research analysts expect that Replimune Group, Inc. will post -2.99 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the stock. Jefferies Financial Group raised their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday. BMO Capital Markets raised their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Roth Mkm assumed coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research note on Friday, November 22nd. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $17.29.
Get Our Latest Research Report on Replimune Group
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Featured Stories
- Five stocks we like better than Replimune Group
- Basic Materials Stocks Investing
- Tesla Poised to Hit Record Highs This Holiday Season
- Ride Out The Recession With These Dividend Kings
- The Salesforce Rally is Just Getting Started: Here’s Why
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL – Free Report).
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.